Abstract
Background Diabetic retinopathy is a leading cause of blindness in adults worldwide. AI with autonomous deep learning algorithms has been increasingly used in the analysis of retinal images particularly for the screening of referrable DR. An established treatment for proliferative DR is pan-retinal or focal laser photocoagulation. Training AI autonomous models to discern laser patterns can be important in disease management and follow-up.
Methods A deep learning model was trained for laser treatment detection using the EyePACs dataset. Data was randomly assigned, by participant, into development (n= 18,945) and validation (n= 2,105) sets. Analysis was conducted at the single image, eye, and patient levels. The model was then used to filter input images for three independent AI models for various retinal indications, and changes in model efficacy were measured using AUC and MAE.
Findings On the task of laser photocoagulation detection: AUC of 0.981 (CI 95% 0.971-0.87) was achieved at the patient level. AUC of 0.950 (CI 95% 0.943-0.956) was achieved at the image level. AUC of 0.979 (CI 95% 0.972-0.984) was achieved at the eye level.
When analyzing independent AI models, efficacy was shown to improve across the board on images of untreated eyes. DME detection on images with artifacts was AUC 0.932 (CI 95% 0.905-0.951) vs. AUC 0.955 (CI 95% 0.948-0.961) on those without. Participant sex detection on images with artifacts was AUC 0.872 (CI 95% 0.830-0.903) compared to AUC 0.922 (CI 95% 0.916-0.927) on those without. Participant age detection on images with artifacts was MAE 5.33 vs. MAE 3.81 on those without.
Interpretation The proposed model for laser treatment detection achieved high performance on all analysis metrics and has been demonstrated to positively affect the efficacy of different AI models, suggesting that laser detection can generally improve AI powered applications for fundus images.
Funding Provided by AEYE Health Inc.
Competing Interest Statement
IB, RA, and YR are employees of AEYE Health. ZDA is CEO of AEYE Health. DM is COO of AEYE Health. SI serves on AEYE Health's board. IB, DM, YR, SI, and ZDA own stock options in AEYE Health.
Funding Statement
This study was funded by AEYE Health, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All images and data were de-identified according to the Health Insurance Portability and Accountability Act Safe Harbor before they were transferred to the researchers. Sterling Institutional Review Board granted an exemption for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are owned by AEYE Health, Inc.
